Reuters| Tokyo | Japan
Fujifilm Holdings Corp said on Wednesday it started a new phase III trial of its anti-influenza drug Avigan in Japan for COVID-19 patients.
The new trial in Japan is targeting patients with early-onset of COVID-19 who have risk factors for progression to severe symptoms, Fujifilm said in a release.
Domestic approval of the drug for COVID-19 was delayed after a health ministry panel said in December that trial data was inconclusive.
(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)
{{#Source}}{{Source}}{{/Source}}{{#IsBlog}}
{{Disclaimer}}
{{/Disclaimer}}